Cipla (CPLFY) Forward PE Ratio: 0.00 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cipla Forward PE Ratio?

Cipla CPLFY 95 Forward PE Ratio is 0.00 as of Jul. 15, 2026. GuruFocus rates CPLFY with a GF Score™ of 95/100. The stock has 5 warning signs investors should review. Among 409 Drug Manufacturers companies, Cipla ranks worse than 71.15% on this metric.

Cipla's Forward PE Ratio for today is 0.00.

Cipla's PE Ratio without NRI for today is 28.22.

Cipla's PE Ratio (TTM) for today is 29.97.

Cipla  (OTCPK:CPLFY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Cipla Forward PE Ratio Related Terms

Cipla Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Cipla's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Forward PE Ratio Chart

Cipla Annual Data
Trend
Forward PE Ratio

Cipla Quarterly Data
Forward PE Ratio

CPLFY vs ZTS, UTHR: Forward PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cipla Forward PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cipla's Forward PE Ratio falls into.


Cipla Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Cipla (CPLFY) has a Forward PE Ratio of 0.00 as of Jul. 15, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cipla and its competitors. According to the industry distribution chart, Cipla ranks #291 out of 409 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is Cipla's Forward PE Ratio too high?
Cipla's current Forward PE Ratio is 0.00. Based on the distribution chart, Cipla ranks #291 out of 409 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #291 out of 409 companies for Forward PE Ratio. This places Cipla in the lower half of its industry. The industry median Forward PE Ratio is 17.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.39, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Cipla's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Cipla (CPLFY), the current Forward PE Ratio is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.